Overview
The Emerging Role of the Gut Microbiome in Reducing Recurrence of C. difficile Infection
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this activity, internal medicine and gastroenterology faculty discuss community- and healthcare-associated C. difficile infection, the increasing incidence of recurrent infection, therapy selection, and when to refer to a specialist. The video-based format, with supporting slides and multidisciplinary panel discussions, provides a comprehensive perspective on the challenges faced by clinicians in the recognition and treatment of initial and recurrent C. difficile infection.
This activity is intended for internal medicine physicians and other clinicians who care for patients at risk of serious infection.
Internal medicine physicians play a critical role in early identification of CDI symptoms, in order to provide appropriate treatment, and refer to a gastroenterologist. When patients describe having gastrointestinal issues, clinicians need to be aware of updated and changing guidelines and treatment options for C. difficile infection. There needs to be better awareness of the role of the gut microbiota, how to approach initial treatment with antibiotics, and available and emerging approaches to gut microbiota restoration. This education is the second in a series of two activities that address the latest data on treating patients who experience recurrent CDI.
Upon completion of this activity, participants will be able to:
• Evaluate the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
• Evaluate the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Paul Feuerstadt MD, FACG, AGAF
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Gastroenterology Center of Connecticut
Sahil Khanna, MBBS, MS
Associate Professor of Medicine
Gastroenterology and Hepatology
Mayo Clinic
Jason Worcester, MD
Assistant Professor of Medicine
Boston Medical Center
Boston University School of Medicine
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
Speakers' Bureau: Merck and Company
Sahil Khanna, MBBS, MS
Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc
Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC
Jason Worcester, MD
No relevant financial relationships to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
By providing your ABIM number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
